Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3

BACKGROUND: Antibody resistance, not only de novo but also acquired cases, usually exists and is related with lower survival rate and high risk of recurrence. Reversing the resistance often results in better clinical therapeutic effect. Previously, we established a trastuzumab-resistant ovarian canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wei, Zhang, Yan, Lv, Ming, Feng, Jiannan, Peng, Hui, Geng, Jing, Lin, Zhou, Zhou, Tingting, Li, Xinying, Shen, Beifen, Ma, Yuanfang, Qiao, Chunxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260252/
https://www.ncbi.nlm.nih.gov/pubmed/25424625
http://dx.doi.org/10.1186/s13048-014-0103-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260252/
https://www.ncbi.nlm.nih.gov/pubmed/25424625
http://dx.doi.org/10.1186/s13048-014-0103-5

Ejemplares similares